UID:
almafu_9959227149402883
Format:
1 online resource (129 p.)
Edition:
1st ed.
ISBN:
0-19-173987-1
,
0-19-960699-4
,
1-283-58075-6
,
9786613893208
,
0-19-157517-8
Series Statement:
Oxford oncology library
Content:
Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging
Note:
Description based upon print version of record.
,
Contents; Contributors; 1 Selection of patients for endocrine therapies; 2 Ovarian ablation; 3 Antioestrogens; 4 Aromatase inhibitors in early and advanced disease; 5 Fulvestrant in metastatic disease; 6 Progestins and androgens; 7 Combined endocrine and chemotherapy in breast cancer; 8 Hormone replacement therapy in patients with a prior history of breast cancer; 9 Chemoprevention; Index; A; B; C; D; E; F; G; H; I; L; M; N; O; P; R; S; T; V; W; Z
,
English
Additional Edition:
ISBN 0-19-921814-5
Language:
English
